Edwards Plans To Keep ‘First-Mover’ Advantage In TAVI Against Emerging Competition
This article was originally published in The Gray Sheet
Executive Summary
Edwards is counting on the Sapien XT valve, which will likely earn FDA approval soon, to compete with Medtronic’s recently approved CoreValve in the U.S, while in Europe the company is working quickly to upgrade customers to Sapien 3.
You may also be interested in...
Edwards’ Third-Generation Sapien TAVI System Launched In Europe
Edwards Lifesciences is launching its Sapien 3 transcatheter aortic valve system in Europe following receipt of a CE mark.
News Briefs: Medtronic’s CoreValve Approval; J&J Dx Unit Set For Sale; Google’s Glucometer Contact Lens
Medtronic gains FDA approval for its transcather CoreValve system months earlier than predicted. The Carlyle Group makes binding offer for J&J’s Ortho-Clinical Diagnostics business. Google is developing a wireless glucometer embedded within a contact lens. More news briefs.
Edwards Wins Latest Round In TAVI Patent Dispute With Medtronic
A jury in Delaware awarded Edwards $393.6 million in damages plus royalties after determining Medtronic’s CoreValve infringes Edwards’ Cribier patent. While Medtronic might be paying royalties to Edwards for the next several years, Medtronic also got some very positive news last week: FDA approved CoreValve for patients too sick for surgery months earlier than expected.